AINDEX
Markets

SeaStar Medical Holding Corporation (ICUCW)

ICUCWNASDAQ-CMMedical/Dental Instruments

$0.00840000

-0.0002 (-2.33%) today

Regular session, Nov 17, 2:44 PM ET

+19.05% 1D
Market cap
$43.6k
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$0.00810000 to $0.0750
Average volume
–
Previous close
$0.00860000

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$420.0k$495.0k$615.0k$635.0k
Gross profit$408.0k$449.0k$561.0k$587.0k
Operating income-$3.02m-$3.60m-$3.79m-$4.58m
Net income-$2.90m-$3.52m-$3.73m-$4.53m

Last four quarters: revenue $2.17m, margin -678.2%, free cash flow –

News

8 latest

The company

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical's first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.

Sector
Health Care
Industry
Medical/Dental Instruments
Exchange
NASDAQ-CM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.